All In Biotech

NDA 211765 · Abbvie

Ubrelvy

Ubrogepant · Oral · Calcitonin Gene-related Peptide Receptor Antagonist

Novel

Last checked: Nov 19, 2026Latest source record: Jun 5, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Dec 23, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

18

7 Phase 3, 1 recruiting

FAERS reports

6,366

2,277 serious, 107 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 29, 2026.

UBRELVY is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use UBRELVY is not indicated for the preventive treatment of migraine. UBRELVY is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use UBRELVY is not indicated for the preventive treatment of migraine. ( 1 )

Mechanism: Ubrogepant is a calcitonin gene-related peptide receptor antagonist.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 23, 2019 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
2 products under this application
  • UBRELVY · UBROGEPANT 50MG · TABLET, ORAL · Prescription
  • UBRELVY · UBROGEPANT 100MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ubrogepant" as an intervention, any sponsor and status, largest first.

All 18 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,069
  • migraine921
  • headache575
  • nausea553
  • fatigue389
  • off label use300
  • dizziness282
  • pain280
  • product dose omission issue240
  • vomiting226
  • pruritus188
  • diarrhoea178

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20151
20169
20171
20184
201917
2020449
2021643
20221,125
2023947
20241,053
20251,096
20261,021

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ubrelvy (Ubrogepant)

2024 spending

$430M

Beneficiaries

83,437

328,213 claims

Per beneficiary

$5,148

$102.07 per unit

View as table
YearSpending
2020$46,916,765
2021$132,378,260
2022$232,438,290
2023$314,665,016
2024$429,537,898

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 52 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.